Y Intercept Hong Kong Ltd decreased its stake in Ralliant Corporation (NYSE:RAL - Free Report) by 54.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,423 shares of the company's stock after selling 56,399 shares during the period. Y Intercept Hong Kong Ltd's holdings in Ralliant were worth $1,972,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Danske Bank A S purchased a new position in Ralliant in the fourth quarter valued at about $25,000. V Square Quantitative Management LLC acquired a new stake in shares of Ralliant during the 4th quarter valued at approximately $26,000. Allworth Financial LP boosted its stake in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company's stock worth $26,000 after acquiring an additional 293 shares in the last quarter. Palisade Asset Management LLC purchased a new stake in shares of Ralliant during the 3rd quarter worth approximately $26,000. Finally, BOKF NA acquired a new stake in shares of Ralliant in the 3rd quarter worth approximately $29,000.
Analysts Set New Price Targets
Several research firms recently weighed in on RAL. TD Cowen raised their price objective on Ralliant from $55.00 to $70.00 and gave the company a "buy" rating in a research note on Wednesday, May 20th. Vertical Research downgraded Ralliant from a "buy" rating to a "hold" rating and set a $65.00 target price on the stock. in a research report on Wednesday, May 27th. Wall Street Zen lowered Ralliant from a "buy" rating to a "hold" rating in a report on Sunday, June 28th. Barclays raised their price target on Ralliant from $52.00 to $67.00 and gave the company an "overweight" rating in a research report on Wednesday, May 13th. Finally, Royal Bank Of Canada lifted their price target on Ralliant from $47.00 to $64.00 and gave the stock a "sector perform" rating in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Ralliant currently has an average rating of "Moderate Buy" and a consensus price target of $69.00.
Get Our Latest Stock Report on RAL
Ralliant Price Performance
RAL stock opened at $68.22 on Thursday. Ralliant Corporation has a 1 year low of $37.27 and a 1 year high of $75.41. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The stock's 50 day moving average price is $62.02 and its 200 day moving average price is $52.32. The firm has a market cap of $7.64 billion and a P/E ratio of -6.24.
Ralliant (NYSE:RAL - Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating analysts' consensus estimates of $0.49 by $0.08. The firm had revenue of $534.60 million for the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company's revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, sell-side analysts expect that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.
Ralliant Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant's dividend payout ratio (DPR) is presently -1.83%.
Ralliant Company Profile
(
Free Report)
Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ralliant, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ralliant wasn't on the list.
While Ralliant currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.